JAGUAR HEALTH, INC. Adjustments to Additional Paid in Capital, Warrant Issued
JAGUAR HEALTH, INC. (JAGX) reported Adjustments to Additional Paid in Capital, Warrant Issued of $4.78 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-19
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-12-31 was $0.00.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-09-30 was $0.00.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-06-30 was $2.98M.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-03-31 was $1.79M.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, warrant issued for fiscal 2025 was $4.78M.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, warrant issued for fiscal 2019 was $493.69K, a 317.85% increase from fiscal 2018.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, warrant issued for fiscal 2018 was $118.15K, a 81.27% decline from fiscal 2017.
- JAGUAR HEALTH, INC. adjustments to additional paid in capital, warrant issued for fiscal 2017 was $630.86K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $0.00 derived: sum of 2 quarters · filed 2026-04-07 | $2.98M derived: sum of 3 quarters · filed 2026-08-19 | $4.78M 10-K · filed 2026-04-07 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.98M derived: sum of 2 quarters · filed 2026-08-19 | $4.78M 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $2.98M 10-Q · filed 2026-08-19 | $4.78M 10-Q · filed 2026-08-19 | |||
| 2025-03-31 | $1.79M 10-Q · filed 2026-05-20 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $494.00K 10-Q · filed 2020-08-13 | $494.00K derived: sum of 3 quarters · filed 2020-08-13 | $494.00K derived: sum of 4 quarters · filed 2020-08-13 | |
| 2020-03-31 | $494.00K 10-Q · filed 2020-05-15 | $494.00K derived: sum of 2 quarters · filed 2020-05-15 | $494.00K derived: sum of 3 quarters · filed 2020-05-15 | $494.00K derived: sum of 4 quarters · filed 2020-05-15 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | $0.00 derived: sum of 2 quarters · filed 2020-04-03 | $0.00 derived: sum of 3 quarters · filed 2020-04-03 | $493.69K 10-K · filed 2020-04-03 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $493.69K 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $493.69K 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $493.69K 10-Q · filed 2019-05-21 | ||||
| 2018-12-31 | $118.15K 10-K · filed 2020-04-03 | ||||
| 2018-09-30 | $118.15K 10-Q · filed 2019-11-14 | ||||
| 2018-08-28 | $494.00K 10-Q · filed 2021-05-17 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | $630.86K 10-K · filed 2019-04-10 | |||
| 2017-09-30 | $630.86K 10-Q · filed 2017-11-20 | ||||
| 2014-12-31 | $114.30K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |